{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:45:12Z","timestamp":1793112312434,"version":"4.5.0"},"reference-count":332,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.autrev.2025.103859","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T12:02:07Z","timestamp":1750680127000},"page":"103859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Chimeric antigen receptor cell therapy: A revolutionary approach transforming cancer treatment to autoimmune disease therapy"],"prefix":"10.1016","volume":"24","author":[{"given":"Ruifan","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jueyi","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnim","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junquan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marady","family":"Hun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimsor","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103859_bb0005","doi-asserted-by":"crossref","first-page":"7424","DOI":"10.7150\/thno.101941","article-title":"Revolutionizing cancer treatment: the emerging potential and potential challenges of in vivo self-processed CAR cell therapy","volume":"14","author":"Lv","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.autrev.2025.103859_bb0010","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/cpt.985","article-title":"Rapid advances in immunotherapy to treat Cancer","volume":"103","author":"McCune","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb0015","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2025.103859_bb0020","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2025.103859_bb0025","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0035","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","article-title":"Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells","volume":"25","author":"Hale","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb0045","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.autrev.2025.103859_bb0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb0055","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","article-title":"CAR T cells for infection, autoimmunity and allotransplantation","volume":"18","author":"Maldini","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","article-title":"Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature","volume":"21","author":"Pokeerbux","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.autrev.2025.103859_bb0070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2025.103859_bb0075","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103859_bb0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","article-title":"Opportunities and limitations of B cell depletion approaches in SLE","volume":"21","author":"Stockfelt","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103859_bb0085","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002907","article-title":"CAR T cells for treating autoimmune diseases","volume":"9","author":"Blache","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103859_bb0095","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0100","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0105","doi-asserted-by":"crossref","first-page":"1432799","DOI":"10.3389\/fimmu.2024.1432799","article-title":"ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights","volume":"15","author":"Ali","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0110","article-title":"Advances in CAR-engineered immune cell generation: engineering approaches and sourcing strategies","volume":"10","author":"Chen","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.autrev.2025.103859_bb0115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.autrev.2025.103859_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.autrev.2025.103859_bb0125","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2020.07.018","article-title":"Multiple signaling roles of CD3\u03b5 and its application in CAR-T cell therapy","volume":"182","author":"Wu","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb0130","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","article-title":"Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells","volume":"96","author":"Brocker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb0135","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nri1248","article-title":"CD28-mediated co-stimulation: a quantitative support for TCR signalling","volume":"3","author":"Acuto","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0140","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.tibtech.2011.04.009","article-title":"Treating cancer with genetically engineered T cells","volume":"29","author":"Park","year":"2011","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.autrev.2025.103859_bb0145","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0150","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.4049\/jimmunol.167.11.6123","article-title":"Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28\/CD3 zeta signaling receptor molecule","volume":"167","author":"Hombach","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0155","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3324\/haematol.2010.026310","article-title":"Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors","volume":"95","author":"Marin","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2025.103859_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci Signal"},{"key":"10.1016\/j.autrev.2025.103859_bb0165","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.autrev.2025.103859_bb0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2025.103859_bb0175","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/mt.2010.313","article-title":"Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb0180","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2025.103859_bb0185","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115691","article-title":"Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma","volume":"168","author":"Yuti","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.autrev.2025.103859_bb0195","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.autrev.2025.103859_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109345","article-title":"CAR cell design strategies in solid tumors","volume":"113","author":"Wang","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2025.103859_bb0205","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tips.2020.11.004","article-title":"Innate and innate-like cells: the future of chimeric antigen receptor (CAR) cell therapy","volume":"42","author":"Cort\u00e9s-Selva","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.autrev.2025.103859_bb0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12928","article-title":"The distinct MHC-unrestricted immunobiology of innate-like and adaptive-like human \u03b3\u03b4 T cell subsets-nature\u2019s CAR-T cells","volume":"298","author":"Willcox","year":"2020","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2025.103859_bb0215","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb0220","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0225","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","article-title":"How do cytotoxic lymphocytes kill Cancer cells?","volume":"21","author":"Mart\u00ednez-Lostao","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.autrev.2025.103859_bb0230","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7150\/jca.48976","article-title":"Current Progress in CAR-T cell therapy for hematological malignancies","volume":"12","author":"Han","year":"2021","journal-title":"J Cancer"},{"key":"10.1016\/j.autrev.2025.103859_bb0235","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.autrev.2025.103859_bb0240","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s43018-023-00570-7","article-title":"Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-\u03b3 is a major determinant of CD4(+) CAR T-cell antitumor activity","volume":"4","author":"Boulch","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.autrev.2025.103859_bb0245","series-title":"Book CAR T-Cell Therapy: Engineering Patients\u2019 Immune Cells to Treat Their Cancers","article-title":"CAR T-Cell Therapy: Engineering Patients\u2019 Immune Cells to Treat Their Cancers","author":"N.C. Institute","year":"2025"},{"key":"10.1016\/j.autrev.2025.103859_bb0250","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40265-017-0690-8","article-title":"Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B-cell malignancies","volume":"77","author":"Hay","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2025.103859_bb0255","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood.V83.8.2045.2045","article-title":"Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines","volume":"83","author":"Gruss","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb0260","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb0265","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.autrev.2025.103859_bb0270","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0275","doi-asserted-by":"crossref","first-page":"9264","DOI":"10.18632\/aging.204405","article-title":"CD229 interacts with RASAL3 to activate RAS\/ERK pathway in multiple myeloma proliferation","volume":"14","author":"Lin","year":"2022","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.autrev.2025.103859_bb0280","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0285","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb0290","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb0295","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2025.103859_bb0300","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR Tcells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0305","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb0310","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41423-019-0344-8","article-title":"Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment","volume":"17","author":"Zhao","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0315","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccell.2022.04.006","article-title":"Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors","volume":"40","author":"Cherkassky","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb0320","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","article-title":"Targeting YAP-dependent MDSC infiltration impairs tumor progression","volume":"6","author":"Wang","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.autrev.2025.103859_bb0325","doi-asserted-by":"crossref","first-page":"16006","DOI":"10.1038\/mto.2016.6","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors","volume":"3","author":"Newick","year":"2016","journal-title":"Mol Ther Oncolyt"},{"key":"10.1016\/j.autrev.2025.103859_bb0330","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.canlet.2021.02.013","article-title":"The tumor microenvironment shapes the molecular characteristics of exhausted CD8(+) T cells","volume":"506","author":"Cheng","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.autrev.2025.103859_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114003","article-title":"Understanding and improving cellular immunotherapies against cancer: from cell-manufacturing to tumor-immune models","volume":"179","author":"Ringquist","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.autrev.2025.103859_bb0340","first-page":"228","article-title":"Target selection of CAR T cell therapy in accordance with the TME for solid tumors","volume":"9","author":"Liu","year":"2019","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.autrev.2025.103859_bb0345","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2025.103859_bb0350","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb0355","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.it.2005.02.007","article-title":"Cellular ligands of activating NK receptors","volume":"26","author":"Bottino","year":"2005","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113860","article-title":"Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: a look into how nanoparticles enhance NK cell activity","volume":"176","author":"Mikelez-Alonso","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.autrev.2025.103859_bb0365","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cell.2020.01.022","article-title":"Tissue determinants of human NK cell development, function, and residence","volume":"180","author":"Dogra","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb0370","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","article-title":"Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb0375","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.it.2017.12.001","article-title":"Natural killer cell education and the response to infection and Cancer therapy: stay tuned","volume":"39","author":"Boudreau","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0380","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.autrev.2025.103859_bb0385","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/2326-6066.CIR-17-0207","article-title":"Intrinsic functional potential of NK-cell subsets constrains retargeting driven by chimeric antigen receptors","volume":"6","author":"Oei","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.autrev.2025.103859_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.autrev.2025.103859_bb0395","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13287-021-02462-y","article-title":"CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb0400","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","article-title":"Regulation of human NK-cell cytokine and chemokine production by target cell recognition","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb0405","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0410","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","article-title":"The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies","volume":"21","author":"Bald","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0415","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0420","doi-asserted-by":"crossref","first-page":"1420205","DOI":"10.3389\/fimmu.2024.1420205","article-title":"The basic biology of NK cells and its application in tumor immunotherapy","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0425","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Sch\u00f6nfeld","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb0430","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb0435","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","article-title":"Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions","volume":"10","author":"Zhong","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.autrev.2025.103859_bb0440","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-023-01435-3","article-title":"CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022","volume":"16","author":"Huang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb0445","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","article-title":"CAR-NK cells for cancer immunotherapy: from bench to bedside","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark Res"},{"key":"10.1016\/j.autrev.2025.103859_bb0450","doi-asserted-by":"crossref","first-page":"eabk3327","DOI":"10.1126\/sciadv.abk3327","article-title":"Extracellular matrix proteins regulate NK cell function in peripheral tissues","volume":"8","author":"Bunting","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.autrev.2025.103859_bb0455","doi-asserted-by":"crossref","DOI":"10.1172\/JCI160584","article-title":"Harnessing allogeneic NK cells: improving outcomes with tailored donor lymphocyte infusion","volume":"132","author":"McCurdy","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2025.103859_bb0460","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.autrev.2025.103859_bb0465","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","article-title":"Natural killer cell homing and trafficking in tissues and tumors: from biology to application","volume":"7","author":"Ran","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb0470","doi-asserted-by":"crossref","first-page":"2002054","DOI":"10.1002\/adma.202002054","article-title":"Engineering macrophages for Cancer immunotherapy and drug delivery","volume":"32","author":"Xia","year":"2020","journal-title":"Adv Mater"},{"key":"10.1016\/j.autrev.2025.103859_bb0475","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jconrel.2024.02.033","article-title":"Adoptive cell therapy for solid tumors beyond CAR-T: current challenges and emerging therapeutic advances","volume":"368","author":"Zhang","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.autrev.2025.103859_bb0480","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"npj Precision Oncology"},{"key":"10.1016\/j.autrev.2025.103859_bb0485","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","article-title":"The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy","volume":"10","author":"Yang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.autrev.2025.103859_bb0490","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00011-024-01907-3","article-title":"Dissection of pro-tumoral macrophage subtypes and immunosuppressive cells participating in M2 polarization","volume":"73","author":"Sezginer","year":"2024","journal-title":"Inflamm Res"},{"key":"10.1016\/j.autrev.2025.103859_bb0495","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.biomaterials.2008.11.025","article-title":"Biomimetic strategies based on viruses and bacteria for the development of immune evasive biomaterials","volume":"30","author":"Novak","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.autrev.2025.103859_bb0500","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004219","article-title":"Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer","volume":"10","author":"Zhu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2025.103859_bb0505","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1479-5876-9-177","article-title":"Tumour macrophages as potential targets of bisphosphonates","volume":"9","author":"Rogers","year":"2011","journal-title":"J Transl Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0510","doi-asserted-by":"crossref","first-page":"1295257","DOI":"10.3389\/fimmu.2023.1295257","article-title":"Tumor-associated macrophages: an effective player of the tumor microenvironment","volume":"14","author":"Basak","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0515","first-page":"263","article-title":"Much more than M1 and M2 macrophages, there are also CD169(+) and TCR(+) macrophages","volume":"6","author":"Ch\u00e1vez-Gal\u00e1n","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0520","doi-asserted-by":"crossref","DOI":"10.3390\/cells11101652","article-title":"Induced CAR-macrophages as a novel therapeutic cell type for Cancer immune cell therapies","volume":"11","author":"Su","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2025.103859_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111605","article-title":"CAR-macrophage: a new immunotherapy candidate against solid tumors","volume":"139","author":"Chen","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.autrev.2025.103859_bb0530","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.autrev.2025.103859_bb0535","doi-asserted-by":"crossref","first-page":"eabn1128","DOI":"10.1126\/scitranslmed.abn1128","article-title":"Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy","volume":"14","author":"Chen","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0540","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12967-023-04479-8","article-title":"The application of HER2 and CD47 CAR-macrophage in ovarian cancer","volume":"21","author":"Chen","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0545","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007705","article-title":"Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia","volume":"11","author":"Abdin","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2025.103859_bb0550","first-page":"166","article-title":"Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity","volume":"67","author":"van Ravenswaay Claasen","year":"1992","journal-title":"Lab Invest"},{"key":"10.1016\/j.autrev.2025.103859_bb0555","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","article-title":"Tumor-associated macrophages: from basic research to clinical application","volume":"10","author":"Yang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb0560","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/imm.12976","article-title":"Macrophage targeting: opening new possibilities for cancer immunotherapy","volume":"155","author":"Cassetta","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2025.103859_bb0565","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","article-title":"CAR macrophages: a promising novel immunotherapy for solid tumors and beyond","volume":"12","author":"Lu","year":"2024","journal-title":"Biomarker Research"},{"key":"10.1016\/j.autrev.2025.103859_bb0570","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41577-018-0034-2","article-title":"Tissue-specific functions of invariant natural killer T cells","volume":"18","author":"Crosby","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0575","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri1309","article-title":"NKT cells: what\u2019s in a name?","volume":"4","author":"Godfrey","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0580","doi-asserted-by":"crossref","first-page":"6304","DOI":"10.1021\/acs.nanolett.1c02238","article-title":"Phototherapy facilitates tumor recruitment and activation of natural killer T cells for potent Cancer immunotherapy","volume":"21","author":"Li","year":"2021","journal-title":"Nano Lett"},{"key":"10.1016\/j.autrev.2025.103859_bb0585","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1158\/1078-0432.CCR-16-0600","article-title":"Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial","volume":"23","author":"Exley","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.autrev.2025.103859_bb0590","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1158\/1078-0432.CCR-06-0114","article-title":"A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer","volume":"12","author":"Motohashi","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.autrev.2025.103859_bb0595","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb0600","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1349-7006.2009.01135.x","article-title":"Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma","volume":"100","author":"Kunii","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.autrev.2025.103859_bb0605","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nri1028","article-title":"Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity","volume":"3","author":"Wilson","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0610","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nri2904","article-title":"Presumed guilty: natural killer T cell defects and human disease","volume":"11","author":"Berzins","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0615","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/nri3725","article-title":"Natural killer T cells: drivers or passengers in preventing human disease?","volume":"14","author":"Berzins","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0620","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri3328","article-title":"Recognition of CD1d-restricted antigens by natural killer T cells","volume":"12","author":"Rossjohn","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0625","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1126\/science.278.5343.1626","article-title":"CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides","volume":"278","author":"Kawano","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.autrev.2025.103859_bb0630","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling natural killer cell responses: integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0635","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.coi.2008.03.018","article-title":"CD1d-restricted iNKT cells, the \u2018Swiss-Army knife\u2019 of the immune system","volume":"20","author":"Matsuda","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0640","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0645","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1182\/blood-2021-149712","article-title":"Allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B-cell malignancies: An interim analysis","volume":"138","author":"Ramos","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb0650","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","article-title":"Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy","volume":"124","author":"Heczey","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb0655","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb0660","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12979-022-00274-z","article-title":"NKT-like (CD3+CD56+) cells differ from T cells in expression level of cellular protective proteins and sensitivity to stimulation in the process of ageing","volume":"19","author":"Kaszubowska","year":"2022","journal-title":"Immunity & Ageing"},{"key":"10.1016\/j.autrev.2025.103859_bb0665","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nri3369","article-title":"Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions","volume":"13","author":"Brennan","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0670","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.stem.2019.08.004","article-title":"Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for Cancer","volume":"25","author":"Zhu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb0675","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1002\/stem.2465","article-title":"Efficient regeneration of human V\u03b124(+) invariant natural killer T cells and their anti-tumor activity in vivo","volume":"34","author":"Yamada","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.autrev.2025.103859_bb0680","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb0685","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1172\/JCI59535","article-title":"IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity","volume":"122","author":"Liu","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2025.103859_bb0690","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","article-title":"Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us","volume":"17","author":"Kabelitz","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0695","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.addr.2017.07.003","article-title":"Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of \u03b3\u03b4 T cells for anticancer immunotherapy","volume":"114","author":"Hodgins","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.autrev.2025.103859_bb0700","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12967-017-1378-2","article-title":"Gamma-delta (\u03b3\u03b4) T cells: friend or foe in cancer development?","volume":"16","author":"Zhao","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0705","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s12276-021-00576-0","article-title":"Function of \u03b3\u03b4 T cells in tumor immunology and their application to cancer therapy","volume":"53","author":"Park","year":"2021","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0710","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/375155a0","article-title":"Natural and synthetic non-peptide antigens recognized by human gamma delta T cells","volume":"375","author":"Tanaka","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2025.103859_bb0715","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nri3904","article-title":"\u0393\u03b4 T cells in cancer","volume":"15","author":"Silva-Santos","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0720","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3389\/fimmu.2018.00929","article-title":"Molecular determinants of target cell recognition by human \u03b3\u03b4 T cells","volume":"9","author":"Sim\u00f5es","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0725","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051206","article-title":"The role of human \u03b3\u03b4 T cells in anti-tumor immunity and their potential for Cancer immunotherapy","volume":"9","author":"Liu","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2025.103859_bb0730","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-023-01722-0","article-title":"Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment","volume":"22","author":"Gao","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.autrev.2025.103859_bb0735","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1126\/science.1110267","article-title":"Professional antigen-presentation function by human gammadelta T cells","volume":"309","author":"Brandes","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.autrev.2025.103859_bb0740","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00262-015-1700-x","article-title":"Myeloid molecular characteristics of human \u03b3\u03b4 T cells support their acquisition of tumor antigen-presenting capacity","volume":"64","author":"Muto","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.autrev.2025.103859_bb0745","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-Delta CAR-T cells show CAR-directed and independent activity against leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0750","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human {{gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2025.103859_bb0755","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","article-title":"Pilot trial of interleukin-2 and zoledronic acid to augment \u03b3\u03b4 T cells as treatment for patients with refractory renal cell carcinoma","volume":"60","author":"Lang","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.autrev.2025.103859_bb0760","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1182\/blood-2008-08-172296","article-title":"Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies","volume":"113","author":"Gertner-Dardenne","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb0765","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2022-157400","article-title":"A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma Delta1 (\u03b3\u03b4) T cells in adults with B-cell malignancies","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb0770","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1182\/blood-2021-147581","article-title":"A phase 1 safety and efficacy study of ADI-001 anti-CD20 CAR-engineered allogeneic Gamma Delta (\u03b3\u03b4) T cells in adults with B cell malignancies, in monotherapy and combination with IL-2","volume":"138","author":"Neelapu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb0775","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3389\/fimmu.2018.01395","article-title":"\u0393\u03b4 T cells and tumor microenvironment: from Immunosurveillance to tumor evasion","volume":"9","author":"Lo Presti","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0780","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0785","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcyt.2024.09.008","article-title":"Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders","volume":"27","author":"Mougiakakos","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.autrev.2025.103859_bb0790","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0795","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gutjnl-2022-327075","article-title":"Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis","volume":"72","author":"Voskens","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2025.103859_bb0800","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2025.103859_bb0805","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92865","article-title":"T cells expressing chimeric antigen receptor promote immune tolerance","volume":"2","author":"Pierini","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2025.103859_bb0810","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2005.11.034","article-title":"Long-term prognosis and causes of death in systemic lupus erythematosus","volume":"119","author":"Doria","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0815","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1053\/j.ajkd.2004.08.047","article-title":"SLE and rapidly progressive glomerulonephritis","volume":"45","author":"Masani","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2025.103859_bb0820","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0825","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000113","article-title":"A prediction model for progressive disease in systemic sclerosis","volume":"1","author":"Meijs","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103859_bb0830","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103859_bb0835","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features","volume":"12","author":"Nombel","year":"2021","journal-title":"Pathogen Emerg Therap Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0840","first-page":"89","article-title":"The potential role of autologous stem cell transplantation in patients with systemic lupus erythematosus","volume":"48","author":"Hahn","year":"1997","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.autrev.2025.103859_bb0845","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-025-01141-w","article-title":"Defining immune reset: achieving sustained remission in autoimmune diseases","author":"Junt","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0850","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2025.103859_bb0855","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-myositis phase I\/II trial","volume":"32","author":"Volkov","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb0860","first-page":"142","article-title":"The role of blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"7","author":"Benjamin","year":"2016","journal-title":"\\"},{"key":"10.1016\/j.autrev.2025.103859_bb0865","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0870","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.954936","article-title":"Role of B cells as antigen presenting cells","volume":"13","author":"Rastogi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0875","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41577-021-00652-6","article-title":"B cells in central nervous system disease: diversity, locations and pathophysiology","volume":"22","author":"Jain","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0880","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41423-022-00933-7","article-title":"Epigenetic regulation of B cells and its role in autoimmune pathogenesis","volume":"19","author":"Xiao","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0885","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12821","article-title":"Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies","volume":"292","author":"Meffre","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2025.103859_bb0890","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1172\/JCI68775","article-title":"Specific peripheral B cell tolerance defects in patients with multiple sclerosis","volume":"123","author":"Kinnunen","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2025.103859_bb0895","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s42255-022-00537-5","article-title":"CAR-based therapies: opportunities for immuno-medicine beyond cancer","volume":"4","author":"Aghajanian","year":"2022","journal-title":"Nat Metab"},{"key":"10.1016\/j.autrev.2025.103859_bb0900","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2025.103859_bb0905","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with Daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0910","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200080","article-title":"CAR-T cell-mediated B-cell depletion in central nervous system autoimmunity","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2025.103859_bb0915","doi-asserted-by":"crossref","first-page":"eadj9730","DOI":"10.1126\/sciimmunol.adj9730","article-title":"Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity","volume":"9","author":"Qin","year":"2024","journal-title":"Sci Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb0920","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0925","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103859_bb0930","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with Antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.autrev.2025.103859_bb0935","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2025.103859_bb0940","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103859_bb0945","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103859_bb0950","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb0955","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2025.103859_bb0960","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.autrev.2025.103859_bb0965","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood-2024-202980","article-title":"CD19 CAR T-cell therapy in refractory autoimmune hemolytic Anemia","volume":"144","author":"Li","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb0970","article-title":"Exploring CAR-macrophages in non-tumor diseases: therapeutic potential beyond cancer","author":"Chen","year":"2025","journal-title":"J Adv Res"},{"key":"10.1016\/j.autrev.2025.103859_bb0975","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2025.103859_bb0980","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41467-023-37785-2","article-title":"Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice","volume":"14","author":"Hu","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103859_bb0985","doi-asserted-by":"crossref","DOI":"10.1038\/s41422-025-01128-1","article-title":"Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus","author":"Yang","year":"2025","journal-title":"Cell Res"},{"key":"10.1016\/j.autrev.2025.103859_bb0990","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1111\/bjh.16266","article-title":"Chimeric antigen receptor T-cell therapy's role in antiphospholipid syndrome: a case report","volume":"188","author":"Schmelz","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2025.103859_bb0995","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.autrev.2025.103859_bb1000","doi-asserted-by":"crossref","first-page":"10335","DOI":"10.1182\/blood-2022-169265","article-title":"Safety and efficacy of CD19 CAR-T cells for refractory systemic sclerosis: a phase I clinical trial","volume":"140","author":"Feng","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb1005","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2025.103859_bb1010","doi-asserted-by":"crossref","first-page":"1298815","DOI":"10.3389\/fimmu.2023.1298815","article-title":"Concurrent remission of lymphoma and Sj\u00f6gren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report","volume":"14","author":"Sheng","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1015","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200292","article-title":"CD19-directed CAR T-cells in a patient with refractory MOGAD: clinical and immunologic follow-up for 1 year","volume":"11","author":"Cabrera-Maqueda","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2025.103859_bb1020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-024-03451-1","article-title":"Immunological effects of CD19.CAR-T cell therapy in systemic sclerosis: an extended case study","volume":"26","author":"Claus","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb1025","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103859_bb1030","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMc2403743","article-title":"Anti-CD19 CAR T cells in refractory immune thrombocytopenia of SLE","volume":"391","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103859_bb1040","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.autrev.2025.103859_bb1045","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1050","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103859_bb1055","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb1060","article-title":"Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome","volume":"5","author":"Wickel","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1065","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1007\/s00415-024-12367-4","article-title":"Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2025.103859_bb1070","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103859_bb1075","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jtha.2024.09.024","article-title":"Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome","volume":"23","author":"Friedberg","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2025.103859_bb1080","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103692","article-title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","volume":"24","author":"He","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103859_bb1085","article-title":"Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission","author":"Wang","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1090","article-title":"Allogenic CD19 CAR NK cells therapy in refractory systemic lupus erythematosus: An open-label, single arm, prospective and interventional clinical trial [abstract]","volume":"vol. 76","author":"Yu","year":"2024","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103859_bb1095","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.autrev.2025.103859_bb1100","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.autrev.2025.103859_bb1105","first-page":"2256","article-title":"GPIb\u03b1 CAAR T cells function like a Trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia","volume":"109","author":"Zhou","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.autrev.2025.103859_bb1110","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb1115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084226","article-title":"Precise targeting of autoantigen-specific B cells in lupus nephritis with chimeric autoantibody receptor T cells","volume":"25","author":"Sol\u00e9","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103859_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19763","article-title":"Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: An in-vitro study","volume":"9","author":"Sahlolbei","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.autrev.2025.103859_bb1125","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb1130","doi-asserted-by":"crossref","first-page":"1511671","DOI":"10.3389\/fimmu.2025.1511671","article-title":"T-regulatory cells for the treatment of autoimmune diseases","volume":"16","author":"Fisher","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fimmu.2012.00051","article-title":"Molecular mechanisms of treg-mediated T cell suppression","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1140","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1145","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.autrev.2025.103859_bb1150","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1155","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature06306","article-title":"The inhibitory cytokine IL-35 contributes to regulatory T-cell function","volume":"450","author":"Collison","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2025.103859_bb1160","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103859_bb1165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102961","article-title":"Flagellin-specific human CAR Tregs for immune regulation in IBD","volume":"134","author":"Boardman","year":"2023","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103859_bb1170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2018.05.003","article-title":"Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells","volume":"92","author":"Kim","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103859_bb1175","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1180","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb1185","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104222","article-title":"Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression","volume":"358","author":"De Paula Pohl","year":"2020","journal-title":"Cell Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1190","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2025.103859_bb1195","doi-asserted-by":"crossref","first-page":"eabn1716","DOI":"10.1126\/scitranslmed.abn1716","article-title":"Pancreatic islet-specific engineered T(regs) exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models","volume":"14","author":"Yang","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103859_bb1205","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.4049\/jimmunol.1701800","article-title":"Targeting antigen-specific B cells using antigen-expressing transduced regulatory T cells","volume":"201","author":"Zhang","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1210","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb1215","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41577-022-00693-5","article-title":"The link between circulating follicular helper T cells and autoimmunity","volume":"22","author":"Walker","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1220","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev-immunol-041015-055605","article-title":"Follicular helper T cells","volume":"34","author":"Vinuesa","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1225","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2567.2011.03487.x","article-title":"The regulation and role of T follicular helper cells in immunity","volume":"134","author":"Deenick","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2025.103859_bb1230","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/cmi.2012.26","article-title":"The darker side of follicular helper T cells: from autoimmunity to immunodeficiency","volume":"9","author":"Shekhar","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1235","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/ni.3054","article-title":"Pathophysiology of T follicular helper cells in humans and mice","volume":"16","author":"Ueno","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1240","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/art.39020","article-title":"Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity","volume":"67","author":"Choi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103859_bb1245","article-title":"Therapeutic targeting of follicular T cells with chimeric antigen receptor-expressing natural killer cells","volume":"1","author":"Reighard","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1250","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-212347","article-title":"A phase 1 study of NKX019, an allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapy in patients with systemic lupus erythematosus","volume":"144","author":"Askanase","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb1255","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clim.2018.04.006","article-title":"La\/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease","volume":"192","author":"Meng","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1260","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.pharmtox.010909.105812","article-title":"Macrophages and tissue injury: agents of defense or destruction?","volume":"51","author":"Laskin","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.autrev.2025.103859_bb1265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40164-017-0083-4","article-title":"Pivotal regulators of tissue homeostasis and cancer: macrophages","volume":"6","author":"Chen","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb1270","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2025.103859_bb1275","doi-asserted-by":"crossref","first-page":"1352946","DOI":"10.3389\/fimmu.2024.1352946","article-title":"Macrophage polarization: an important role in inflammatory diseases","volume":"15","author":"Luo","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1280","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1073\/pnas.0914902107","article-title":"Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages","volume":"107","author":"Triantafyllopoulou","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2025.103859_bb1285","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/MIB.0b013e3182a69dca","article-title":"The role of macrophages and dendritic cells in the initiation of inflammation in IBD","volume":"20","author":"Steinbach","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2025.103859_bb1290","doi-asserted-by":"crossref","first-page":"8821610","DOI":"10.1155\/2023\/8821610","article-title":"Regulatory mechanism of M1\/M2 macrophage polarization in the development of autoimmune diseases","volume":"2023","author":"Peng","year":"2023","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.autrev.2025.103859_bb1295","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","article-title":"Macrophage-based approaches for Cancer immunotherapy","volume":"81","author":"Anderson","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2025.103859_bb1300","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","article-title":"The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors","volume":"11","author":"Hadiloo","year":"2023","journal-title":"Biomark Res"},{"key":"10.1016\/j.autrev.2025.103859_bb1305","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymthe.2017.10.012","article-title":"Retroviral and lentiviral safety analysis of gene-modified T cell products and infused HIV and oncology patients","volume":"26","author":"Marcucci","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb1310","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb1315","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.autrev.2025.103859_bb1320","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb1325","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"438","key":"10.1016\/j.autrev.2025.103859_bb1330","first-page":"e1","article-title":"Immune effector cell-associated Hemophagocytic Lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb1335","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb1340","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1345","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"issue":"2025","key":"10.1016\/j.autrev.2025.103859_bb1350","article-title":"The design of retroviral vectors used in the CAR-T products, risk management, and future perspective","volume":"6","author":"Yin","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.autrev.2025.103859_bb1355","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.autrev.2025.103859_bb1360","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2025.103859_bb1365","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26030965","article-title":"Optimal chimeric antigen receptor (CAR)-mRNA for transient CAR T cell generation","volume":"26","author":"Kitte","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103859_bb1370","series-title":"Book FDA investigating serious risk of T-cell Malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies","article-title":"FDA investigating serious risk of T-cell Malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies (2023)","author":"Food","year":"2023"},{"key":"10.1016\/j.autrev.2025.103859_bb1375","series-title":"Book EBMT reaches major milestone: 10,000 CAR-T treated patients registered in its registry","article-title":"EBMT reaches major milestone: 10,000 CAR-T treated patients registered in its registry","author":"E.S.f.B.a.M.T. (EBMT)","year":"2024"},{"key":"10.1016\/j.autrev.2025.103859_bb1380","first-page":"222","article-title":"Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transplantat Cell Therap Off Publicat Am Soc Transplantat Cell Therap"},{"key":"10.1016\/j.autrev.2025.103859_bb1385","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2025.04.002","article-title":"Mechanisms underlying resistance to CAR-T cell therapy and strategies for enhancement","author":"Wu","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.autrev.2025.103859_bb1390","first-page":"1119","article-title":"Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy","volume":"56","author":"Wang","year":"2024","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.autrev.2025.103859_bb1395","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1400","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192203","article-title":"Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression","volume":"218","author":"Lanitis","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1405","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb1410","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2025.103859_bb1415","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103229","article-title":"Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Shu","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.autrev.2025.103859_bb1420","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO-24-01933","article-title":"Allogeneic chimeric antigen receptor T-cell products Cemacabtagene Ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: phase I experience from the ALPHA2\/ALPHA clinical studies","volume":"43","author":"Locke","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb1425","doi-asserted-by":"crossref","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1430","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00262-018-2155-7","article-title":"Induction of a central memory and stem cell memory phenotype in functionally active CD4(+) and CD8(+) CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19(+) acute lymphoblastic leukemia","volume":"67","author":"Blaeschke","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.autrev.2025.103859_bb1435","first-page":"S406","article-title":"Medicare utilization and cost trends for CAR-T cell therapies in the treatment of large B-cell lymphoma","volume":"30","author":"Wu","year":"2024","journal-title":"Transplantat Cell Therap Off Publicat Am Soc Transplantat Cell Therap"},{"key":"10.1016\/j.autrev.2025.103859_bb1440","series-title":"High cost of chimeric antigen receptor T-cells: Challenges and solutions","first-page":"e397912","author":"Cliff","year":"2023"},{"key":"10.1016\/j.autrev.2025.103859_bb1445","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.37765\/ajmc.2021.88737","article-title":"Improving outcomes and mitigating costs associated with CAR T-cell therapy","volume":"27","author":"Borgert","year":"2021","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.autrev.2025.103859_bb1450","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s40273-024-01430-7","article-title":"Different models, same results: considerations when choosing between approaches to model cost effectiveness of chimeric-antigen receptor T-cell therapy versus standard of care","volume":"42","author":"Gye","year":"2024","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.autrev.2025.103859_bb1455","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213428","article-title":"Cost trends of new-to-market neurologic medications","volume":"104","author":"Gusovsky Chevalier","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103859_bb1460","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/ar1208","article-title":"Lymphopenia and autoimmune diseases","volume":"6","author":"Schulze-Koops","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb1465","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004185","article-title":"To go or not to go? Biological logic gating engineered T cells","volume":"10","author":"Abbott","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2025.103859_bb1470","doi-asserted-by":"crossref","first-page":"1407992","DOI":"10.3389\/fimmu.2024.1407992","article-title":"Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies","volume":"15","author":"Alviano","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103859_bb1475","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-143474","article-title":"Tandem CD19\/CD22 dual targets CAR-T cells therapy acquires superior CR rate than CD19 CAR-T cells: a case controlled study","volume":"136","author":"Cui","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb1480","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.autrev.2025.103859_bb1485","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004727","article-title":"Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel","volume":"10","author":"Szabo","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103859_bb1490","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb1495","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1500","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb1505","article-title":"Manufacturing of IMPT-514, a CD19\/CD20 bispecific CAR T cell product candidate as a potential treatment of patients with autoimmune diseases","volume":"76","author":"David","year":"2024","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103859_bb1510","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.hlife.2024.05.005","article-title":"BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy","volume":"2","author":"Zhang","year":"2024","journal-title":"hLife"},{"key":"10.1016\/j.autrev.2025.103859_bb1515","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12974-024-03262-w","article-title":"MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis","volume":"21","author":"Frikeche","year":"2024","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2025.103859_bb1520","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-016-1653-y","article-title":"An updated histological classification system for multiple sclerosis lesions","volume":"133","author":"Kuhlmann","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.autrev.2025.103859_bb1525","article-title":"Targeting human plasma cells using regulated BCMA CAR T cells eliminates circulating antibodies in humanized mice","author":"Honaker","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.autrev.2025.103859_bb1530","doi-asserted-by":"crossref","first-page":"eadl4793","DOI":"10.1126\/science.adl4793","article-title":"Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs","volume":"386","author":"Reddy","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.autrev.2025.103859_bb1535","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb1540","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb1545","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2025.103859_bb1550","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1555","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2326-6066.CIR-16-0043","article-title":"A Tet-on inducible system for controlling CD19-chimeric antigen receptor expression upon drug Administration","volume":"4","author":"Sakemura","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.autrev.2025.103859_bb1560","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113455","article-title":"Development of inducible CD19-CAR T cells with a Tet-on system for controlled activity and enhanced clinical safety","volume":"19","author":"Gu","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103859_bb1565","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.ccell.2022.10.019","article-title":"Let’s turn the CAR-T cells ON and OFF precisely","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb1570","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","article-title":"High-performance multiplex drug-gated CAR circuits","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.autrev.2025.103859_bb1575","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1580","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41571-021-00479-z","article-title":"Cancer therapies based on targeted protein degradation \u2014 lessons learned with lenalidomide","volume":"18","author":"Jan","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb1585","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.autrev.2025.103859_bb1590","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood.V97.1.63","article-title":"Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft","volume":"97","author":"Tiberghien","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb1595","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.autrev.2025.103859_bb1600","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103859_bb1605","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb1610","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1089\/hgtb.2012.050","article-title":"Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells","volume":"23","author":"Marin","year":"2012","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.autrev.2025.103859_bb1615","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/blood-2005-09-3775","article-title":"Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes","volume":"107","author":"Cl\u00e9menceau","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103859_bb1620","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-11-3890","article-title":"A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor","volume":"72","author":"Urbanska","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2025.103859_bb1625","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41551-023-01048-8","article-title":"Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR","volume":"7","author":"Zhang","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.autrev.2025.103859_bb1630","doi-asserted-by":"crossref","first-page":"E690","DOI":"10.1073\/pnas.1115485109","article-title":"Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin","volume":"109","author":"Zakeri","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2025.103859_bb1635","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","article-title":"Engineering advanced logic and distributed computing in human CAR immune cells","volume":"12","author":"Cho","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103859_bb1640","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s42003-020-1021-2","article-title":"convertibleCARs: a chimeric antigen receptor system for flexible control of activity and antigen targeting","volume":"3","author":"Landgraf","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.autrev.2025.103859_bb1645","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1038\/s41467-023-37863-5","article-title":"Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting","volume":"14","author":"Ruffo","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103859_bb1650","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1126\/science.aba6527","article-title":"Designed protein logic to target cells with precise combinations of surface antigens","volume":"369","author":"Lajoie","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.autrev.2025.103859_bb1655","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.autrev.2025.103859_bb1660","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1002\/anie.201601902","article-title":"Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer","volume":"55","author":"Cao","year":"2016","journal-title":"Angew Chem Int Ed Engl"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T03:09:19Z","timestamp":1754795359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":332,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1568997225001193"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103859","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor cell therapy: A revolutionary approach transforming cancer treatment to autoimmune disease therapy","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103859"}}